09:51 AM EST - Resverlogix Corp. : Announced recent published findings in the high-impact journal, Proceedings of the National Academy of Sciences (PNAS),that further supports other 2020 publications and provides new evidence for the therapeutic potential of BET inhibitors in the treatment of COVID-19. A publication titled: “Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2”, highlights the important role that host cell receptors play in enabling viral entry into cells, and presents direct evidence that BET inhibitors reduce SARS-CoV-2 (the scientific name for the virus responsible for COVID-19) infection by inhibiting the expression of these receptors. The publication also acknowledges Resverlogix and the Company’s plans to confirm the hypothesis with a clinical trial utilizing its advanced BET inhibition technology. Resverlogix Corp.
shares T.RVX are trading up $0.07 at $1.08.
